Table 1.

Preoperative features

Preoperative features	Number of patients with feature/total number of patients with available data (%)
Mass effect symptoms	11/25 (44)
Macroadenomas	21/27 (78)
Suprasellar extension	11/23 (48)
Optic chiasm compression	9/23 (39)
Cavernous sinus invasion	7/19 (37)
Knosp score         0	3/14 (21)
1	4/14 (29)
2	3/14 (21)
3	0/14 (0)
4	4/14 (29)
Carotid encasement	2/19 (11)
Sphenoid sinus invasion	5/19 (26)
Cystic components	4/29 (14)
Tumor hemorrhage	3/29 (10)
Intracranial extension	2/19 (11)
Any hypopituitarism	22/29 (76)
ACTH deficiency	3/22 (14)
TSH deficiency	4/23 (17)
GH deficiency	3/18 (17)
FSH/LH deficiency	21/23 (91)
DA treatment
Use of DA preoperatively	21/27 (78)
Achieved tumor reduction on DA	2/15 (13)
Achieved PRL normalization on DA	5/16 (31)
Achieved PRL reduction on DA	14/16 (88)
Subjects classified as DA intolerant	12/21 (57)
Subjects classified as DA resistant	13/21 (62)